Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis.

Kreitz K, Ernst A, Schmidt R, Simon T, Fischer M, Volland R, Hero B, Berthold F.

Cancer Med. 2019 Oct 20. doi: 10.1002/cam4.2562. [Epub ahead of print]

2.

Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T.

Br J Cancer. 2019 Sep 24. doi: 10.1038/s41416-019-0592-5. [Epub ahead of print]

PMID:
31551583
3.

A mechanistic classification of clinical phenotypes in neuroblastoma.

Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M.

Science. 2018 Dec 7;362(6419):1165-1170. doi: 10.1126/science.aat6768.

PMID:
30523111
4.

Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T.

Br J Cancer. 2018 Aug;119(3):282-290. doi: 10.1038/s41416-018-0169-8. Epub 2018 Jul 11. Erratum in: Br J Cancer. 2019 Sep 24;:.

5.

LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.

Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, de Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C.

Clin Cancer Res. 2018 Nov 15;24(22):5772-5783. doi: 10.1158/1078-0432.CCR-17-2578. Epub 2018 Jun 20.

PMID:
29925504
6.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

7.

Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome.

Hero B, Clement N, Øra I, Pierron G, Lapouble E, Theissen J, Pasqualini C, Valteau-Couanet D, Plantaz D, Michon J, Delattre O, Tardieu M, Schleiermacher G.

J Pediatr Hematol Oncol. 2018 Mar;40(2):93-98. doi: 10.1097/MPH.0000000000000976.

PMID:
29135842
8.

Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.

Rosswog C, Schmidt R, Oberthuer A, Juraeva D, Brors B, Engesser A, Kahlert Y, Volland R, Bartenhagen C, Simon T, Berthold F, Hero B, Faldum A, Fischer M.

Neoplasia. 2017 Dec;19(12):982-990. doi: 10.1016/j.neo.2017.09.006. Epub 2017 Nov 5.

9.

Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G.

J Pediatr Surg. 2018 Mar;53(3):558-566. doi: 10.1016/j.jpedsurg.2017.09.002. Epub 2017 Sep 11.

PMID:
29021103
10.

Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I.

Krosschell KJ, Kissel JT, Townsend EL, Simeone SD, Zhang RZ, Reyna SP, Crawford TO, Schroth MK, Acsadi G, Kishnani PS, Von Kleist-Retzow JC, Hero B, D'Anjou G, Smith EC, Elsheikh B, Simard LR, Prior TW, Scott CB, Lasalle B, Sakonju A, Wirth B, Swoboda KJ; Project Cure SMA Investigator's Network.

Muscle Nerve. 2018 Feb;57(2):193-199. doi: 10.1002/mus.25776. Epub 2017 Sep 18.

PMID:
28833236
11.

Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.

Fischer J, Pohl A, Volland R, Hero B, Dübbers M, Cernaianu G, Berthold F, von Schweinitz D, Simon T.

BMC Cancer. 2017 Aug 4;17(1):520. doi: 10.1186/s12885-017-3493-0.

12.

2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.

Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A.

Klin Padiatr. 2017 May;229(3):147-167. doi: 10.1055/s-0043-103086. Epub 2017 May 30.

PMID:
28561228
13.

Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology.

Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, Debatin KM, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Frühwald MC, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Körholz D, Koscielniak E, Kramm CM, Kuhlen M, Kulozik AE, Lamottke B, Leuschner I, Lohmann DR, Meinhardt A, Metzler M, Meyer LH, Moser O, Nathrath M, Niemeyer CM, Nustede R, Pajtler KW, Paret C, Rasche M, Reinhardt D, Rieß O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, von Bueren AO, Vorwerk P, Witt O, Wlodarski M, Wössmann W, Zenker M, Zimmermann S, Pfister SM, Kratz CP.

Am J Med Genet A. 2017 Apr;173(4):1017-1037. doi: 10.1002/ajmg.a.38142. Epub 2017 Feb 7. Review.

PMID:
28168833
14.

Long-term follow-up of meningeal spread of otherwise stage 4S neuroblastoma without treatment.

Meinhardt A, Becker B, Hero B, Gramsch C, Steiner D, Woessmann W.

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26445. Epub 2017 Jan 18. No abstract available.

PMID:
28097782
15.

Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S.

Holsten T, Schuster T, Grabhorn E, Hero B, Frühwald MC.

Pediatr Hematol Oncol. 2017 Feb;34(1):17-23. doi: 10.1080/08880018.2016.1266535. Epub 2017 Jan 13.

PMID:
28085536
16.

Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ.

Eur J Cancer. 2017 Feb;72:177-185. doi: 10.1016/j.ejca.2016.11.022. Epub 2016 Dec 26.

17.

Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.

Schumacher-Kuckelkorn R, Volland R, Gradehandt A, Hero B, Simon T, Berthold F.

Pediatr Blood Cancer. 2017 Jan;64(1):46-56. doi: 10.1002/pbc.26184. Epub 2016 Sep 22.

PMID:
27654028
18.

Early vibration assisted physiotherapy in toddlers with cerebral palsy - a randomized controlled pilot trial.

Stark C, Herkenrath P, Hollmann H, Waltz S, Becker I, Hoebing L, Semler O, Hoyer-Kuhn H, Duran I, Hero B, Hadders-Algra M, Schoenau E.

J Musculoskelet Neuronal Interact. 2016 Sep 7;16(3):183-92.

19.

IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks.

Hayn D, Falgenhauer M, Kropf M, Nitzlnader M, Welte S, Ebner H, Ladenstein R, Schleiermacher G, Hero B, Schreier G.

Stud Health Technol Inform. 2016;228:287-91.

PMID:
27577389
20.

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE.

Oncotarget. 2016 Oct 11;7(41):66344-66359. doi: 10.18632/oncotarget.11662.

21.

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK.

Damm-Welk C, Siddiqi F, Fischer M, Hero B, Narayanan V, Camidge DR, Harris M, Burke A, Lehrnbecher T, Pulford K, Oschlies I, Siebert R, Turner S, Woessmann W.

J Cancer. 2016 Jun 30;7(11):1383-7. doi: 10.7150/jca.15238. eCollection 2016.

22.

Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed.

Decarolis B, Simon T, Krug B, Leuschner I, Vokuhl C, Kaatsch P, von Schweinitz D, Klingebiel T, Mueller I, Schweigerer L, Berthold F, Hero B.

BMC Cancer. 2016 Jul 27;16:542. doi: 10.1186/s12885-016-2513-9.

23.

Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.

Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O.

J Musculoskelet Neuronal Interact. 2016 Mar;16(1):24-32.

24.

Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.

van Wezel EM, Decarolis B, Stutterheim J, Zappeij-Kannegieter L, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, van Noesel MM, Caron HN, van der Schoot CE, Hero B, Tytgat GAM.

Eur J Cancer. 2016 Feb;54:149-158. doi: 10.1016/j.ejca.2015.11.007. Epub 2016 Jan 12.

PMID:
26796600
25.

Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.

Ikram F, Ackermann S, Kahlert Y, Volland R, Roels F, Engesser A, Hertwig F, Kocak H, Hero B, Dreidax D, Henrich KO, Berthold F, Nürnberg P, Westermann F, Fischer M.

Mol Oncol. 2016 Feb;10(2):344-59. doi: 10.1016/j.molonc.2015.10.020. Epub 2015 Nov 7.

26.

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M.

Nature. 2015 Oct 29;526(7575):700-4. doi: 10.1038/nature14980. Epub 2015 Oct 14.

27.

Correction factors for self-selection when evaluating screening programmes.

Spix C, Berthold F, Hero B, Michaelis J, Schilling FH.

J Med Screen. 2016 Mar;23(1):44-9. doi: 10.1177/0969141315597959. Epub 2015 Jul 29.

PMID:
26223516
28.

Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma.

Lindner S, Bachmann HS, Odersky A, Schaefers S, Klein-Hitpass L, Hero B, Fischer M, Eggert A, Schramm A, Schulte JH.

Biomed Rep. 2015 Jul;3(4):443-446. Epub 2015 May 13.

29.

From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML.

Krumbholz M, Bradtke J, Stachel D, Peters O, Hero B, Holter W, Slany R, Metzler M.

Bone Marrow Transplant. 2015 Oct;50(10):1382-4. doi: 10.1038/bmt.2015.155. Epub 2015 Jul 6. No abstract available.

PMID:
26146805
30.

Mutational dynamics between primary and relapse neuroblastomas.

Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH.

Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29.

PMID:
26121086
31.

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M.

Genome Biol. 2015 Jun 25;16:133. doi: 10.1186/s13059-015-0694-1.

32.

Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.

van Wezel EM, Stutterheim J, Vree F, Zappeij-Kannegieter L, Decarolis B, Hero B, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, Voermans C, van Noesel MM, Caron HN, van der Schoot CE, Tytgat GA; GPOH MRD Study Group.

Pediatr Blood Cancer. 2015 Aug;62(8):1368-73. doi: 10.1002/pbc.25507. Epub 2015 May 4.

PMID:
25939774
33.

Rationale, design and objectives of ARegPKD, a European ARPKD registry study.

Ebner K, Feldkoetter M, Ariceta G, Bergmann C, Buettner R, Doyon A, Duzova A, Goebel H, Haffner D, Hero B, Hoppe B, Illig T, Jankauskiene A, Klopp N, König J, Litwin M, Mekahli D, Ranchin B, Sander A, Testa S, Weber LT, Wicher D, Yuzbasioglu A, Zerres K, Dötsch J, Schaefer F, Liebau MC; ESCAPE Study Group; GPN Study Group.

BMC Nephrol. 2015 Feb 18;16:22. doi: 10.1186/s12882-015-0002-z.

34.

Sample size calculation for the one-sample log-rank test.

Schmidt R, Kwiecien R, Faldum A, Berthold F, Hero B, Ligges S.

Stat Med. 2015 Mar 15;34(6):1031-40. doi: 10.1002/sim.6394. Epub 2014 Dec 11.

PMID:
25500942
35.

FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.

Ackermann S, Kocak H, Hero B, Ehemann V, Kahlert Y, Oberthuer A, Roels F, Theißen J, Odenthal M, Berthold F, Fischer M.

BMC Cancer. 2014 Nov 18;14:840. doi: 10.1186/1471-2407-14-840.

36.

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.

Bleeker G, van Eck-Smit BL, Zwinderman KH, Versteeg R, van Noesel MM, Kam BL, Kaspers GJ, van Schie A, Kreissman SG, Yanik G, Hero B, Schmidt M, Laureys G, Lambert B, Øra I, Schulte JH, Caron HN, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):222-30. doi: 10.1007/s00259-014-2909-1. Epub 2014 Sep 30.

37.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

38.

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG.

J Clin Oncol. 2014 Oct 1;32(28):3169-76. doi: 10.1200/JCO.2014.56.1621. Epub 2014 Aug 25.

39.

Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.

Theissen J, Oberthuer A, Hombach A, Volland R, Hertwig F, Fischer M, Spitz R, Zapatka M, Brors B, Ortmann M, Simon T, Hero B, Berthold F.

Genes Chromosomes Cancer. 2014 Aug;53(8):639-49. doi: 10.1002/gcc.22174. Epub 2014 Apr 15.

PMID:
24737690
40.

Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

J Clin Oncol. 2014 Apr 20;32(12):1228-35. doi: 10.1200/JCO.2013.53.6342. Epub 2014 Mar 24.

41.

Rare malignant pediatric tumors registered in the German Childhood Cancer Registry 2001-2010.

Brecht IB, Bremensdorfer C, Schneider DT, Frühwald MC, Offenmüller S, Mertens R, Vorwerk P, Koscielniak E, Bielack SS, Benesch M, Hero B, Graf N, von Schweinitz D, Kaatsch P.

Pediatr Blood Cancer. 2014 Jul;61(7):1202-9. doi: 10.1002/pbc.24997. Epub 2014 Feb 28.

PMID:
24585499
42.

GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.

Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, Kopp-Schneider A, Opitz L, Capper D, von Deimling A, Wiegand I, Milde T, Mahlknecht U, Westermann F, Popanda O, Roels F, Hero B, Berthold F, Fischer M, Kulozik AE, Witt O, Deubzer HE.

Cancer Res. 2014 May 1;74(9):2604-16. doi: 10.1158/0008-5472.CAN-13-1904. Epub 2014 Jan 13.

43.

Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.

Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, Hoppe B.

Clin J Am Soc Nephrol. 2014 Mar;9(3):468-77. doi: 10.2215/CJN.06820613. Epub 2014 Jan 2.

44.

Update on pediatric opsoclonus myoclonus syndrome.

Hero B, Schleiermacher G.

Neuropediatrics. 2013 Dec;44(6):324-9. doi: 10.1055/s-0033-1358604. Epub 2013 Nov 7. Review.

PMID:
24203854
45.

A method for finding consensus breakpoints in the cancer genome from copy number data.

Toloşi L, Theißen J, Halachev K, Hero B, Berthold F, Lengauer T.

Bioinformatics. 2013 Jul 15;29(14):1793-800. doi: 10.1093/bioinformatics/btt300. Epub 2013 May 28.

PMID:
23716195
46.

Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma.

Kocak H, Ackermann S, Hero B, Kahlert Y, Oberthuer A, Juraeva D, Roels F, Theissen J, Westermann F, Deubzer H, Ehemann V, Brors B, Odenthal M, Berthold F, Fischer M.

Cell Death Dis. 2013 Apr 11;4:e586. doi: 10.1038/cddis.2013.84.

47.

Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.

Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, Dietlein M, Berthold F, Schmidt M.

J Clin Oncol. 2013 Mar 1;31(7):944-51. doi: 10.1200/JCO.2012.45.8794. Epub 2013 Jan 22.

PMID:
23341514
48.

Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis.

Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F.

J Clin Oncol. 2013 Feb 20;31(6):752-8. doi: 10.1200/JCO.2012.45.9339. Epub 2013 Jan 2.

PMID:
23284039
49.

[18F]Fluorodeoxyglucose positron emission tomography/computed tomography-positive gastric adenocarcinoma in a 12-year-old girl with Peutz-Jeghers syndrome.

Schneider C, Simon T, Hero B, Uphoff US, Drebber U, Alakus H, Holinski-Feder E, Berthold F, Dietlein M, Schmidt MC.

J Clin Oncol. 2012 May 10;30(14):e140-3. doi: 10.1200/JCO.2011.39.7422. Epub 2012 Apr 9. No abstract available.

PMID:
22493416
50.

Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma.

Simon T, Niemann CA, Hero B, Henze G, Suttorp M, Schilling FH, Berthold F.

Dev Med Child Neurol. 2012 Apr;54(4):347-52. doi: 10.1111/j.1469-8749.2012.04219.x. Epub 2012 Feb 13.

Supplemental Content

Support Center